PORT MATILDA, Pa., Aug. 25 /PRNewswire-FirstCall/ — QBC
Diagnostics was awarded one of the largest contracts in company
history, as the United States Navy has agreed to install QBC STAR
hematology analyzers on surface ships throughout the world.
The QBC STAR provides users a 9-parameter complete blood count
through its patented dry hematology approach, which eliminates the
need for liquid reagents. Because of this technology, as well as
the unit’s small footprint and internal calibration system, the
STAR can be transported easily and provide accurate patient results
Ken Moscone, President and CEO of QBC Diagnostics, said, “We are
incredibly pleased to bring the benefits of the QBC STAR to the men
and women of the United States Navy. The STAR possesses many
features that will help to keep our servicemen and women healthy as
they protect our country.
“Our line of hematology products are especially well suited for
use in the military environment,” Moscone continued. “With
one-button operation, no start-up requirements, and the use of
simple blood collection tubes, the STAR is robust, designed to go
anywhere and provide results quickly. Unlike liquid reagents, dry
QBC technology is not adversely affected by the pitch and roll of a
ship, making it especially well-suited for use on Navy
For more information on the QBC STAR, please consult the QBC
Diagnostics website at http://www.qbcdiagnostics.com/products/hema/star/fab.asp.
About QBC Diagnostics
QBC Diagnostics is a privately held company headquartered in
Port Matilda, Pennsylvania, USA. The company manufactures a line of
complete blood count analyzers and fluorescence microscopy
products. Additional information can be found by visiting the
company website (www.qbcdiagnostics.com)
or by calling 814-692-7661.